A Comparison of Differences Between the Systemic Pharmacokinetics of Levobupivacaine and Ropivacaine During Continuous Epidural Infusion: A Prospective, Randomized, Multicenter, Double-Blind Controlled Trial

Luciano Perotti, Maria Cusato, Pablo Ingelmo, Thekla Larissa Niebel, Marta Somaini, Francesca Riva, Carmine Tinelli, José De Andrés, Guido Fanelli, Antonio Braschi, Mario Regazzi, Massimo Allegri, Luciano Perotti, Maria Cusato, Pablo Ingelmo, Thekla Larissa Niebel, Marta Somaini, Francesca Riva, Carmine Tinelli, José De Andrés, Guido Fanelli, Antonio Braschi, Mario Regazzi, Massimo Allegri

Abstract

Background: Epidural infusion of levobupivacaine and ropivacaine provides adequate postoperative pain management by minimizing side effects related to IV opioids and improving patient outcome. The safety profile of different drugs can be better estimated by comparing their pharmacokinetic profiles than by considering their objective side effects. Because levobupivacaine and ropivacaine have different pharmacokinetic properties, our aim was to investigate whether there is a difference in the pharmacokinetic variability of the 2 drugs in a homogeneous population undergoing continuous epidural infusion. This double-blind, multicenter, randomized, controlled trial study was designed to compare the pharmacokinetics of continuous thoracic epidural infusion of levobupivacaine 0.125% or ropivacaine 0.2% for postoperative pain management in adult patients who had undergone major abdominal, urological, or gynecological surgery. This study is focused on the evaluation of the coefficient of variation (CV) to assess the equivalence in the systemic exposure and interindividual variability between levobupivacaine and ropivacaine and, therefore, the possible differences in the predictability of the plasmatic concentrations of the 2 drugs during thoracic epidural infusion.

Methods: One hundred eighty-one adults undergoing major abdominal surgery were enrolled in the study. Patients were randomized to receive an epidural infusion of levobupivacaine 0.125% + sufentanil 0.75 μg/mL or of ropivacaine 0.2% + sufentanil 0.75 μg/mL at 5 mL/h for 48 hours. The primary end point of this study was to analyze the variability of plasma concentration of levobupivacaine and ropivacaine via an area under the curve within a range of 15% of the CV during 48 hours of continuous epidural infusion. The CV shows how the concentration values of local anesthetics are scattered around the median concentration value, thus indicating the extent to which plasma concentration is predictable during infusion. Secondary end points were to assess the pharmacologic profile of the local anesthetics used in the study, including an analysis of mean peak plasma concentrations, and also to assess plasma clearance, side effects, pain intensity (measured with a verbal numeric ranging score, i.e., static Numeric Rating Scale [NRS] and dynamic NRS]), and the need for rescue doses.

Results: The comparison between the 2 CVs showed no statistical difference: the difference between area under the curve was within the range of 15%. The CV was 0.54 for levobupivacaine and 0.51 for ropivacaine (P = 0.725). The plasma concentrations of ropivacaine approached the Cmax significantly faster than those of levobupivacaine. Clearance of ropivacaine decreases with increasing patient age. There were no significant differences in NRS, dynamic NRS scores, the number of rescue doses, or in side effects between groups.

Conclusions: Considering the CV, the interindividual variability of plasma concentration for levobupivacaine and ropivacaine is equivalent after thoracic epidural infusion in adults. We found a reduction in clearance of ropivacaine depending on patient age, but this finding could be the result of some limitations of our study. The steady-state concentration was not reached during the 48-hour infusion and the behavior of plasma concentrations of ropivacaine and levobupivacaine during continuous infusions lasting more than 48 hours remains to be investigated, because they could reach toxic levels. Finally, no differences in the clinical efficacy or in the incidence of adverse effects between groups were found for either local anesthetic.

Trial registration: ClinicalTrials.gov NCT01229241.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Consort diagram: flow of patients through the study.
Figure 2.
Figure 2.
Total plasma drug concentration versus time curves during and after epidural continuous infusion preceded by 2 sequential boluses. L-BPV = levobupivacaine; RPV = ropivacaine.
Figure 3.
Figure 3.
Correlation between clearance and patients’ age for levobupivacaine and ropivacaine (Dashed lines are 95% confidence interval of regression line).

References

    1. Rigg JR, Jamrozik K, Myles PS, Silbert BS, Peyton PJ, Parsons RW, Collins KS MASTER Anaethesia Trial Study Group. Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial. Lancet. 2002;359:1276–82.
    1. Albaladejo P, Bouaziz H, Benhamou D. Epidural analgesics: how can safety and efficacy be improved? CNS Drugs. 1998;10:91–104.
    1. Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. Anesthesiology. 2011;115:181–8.
    1. Sanford M, Keating GM. Levobupivacaine: a review of its use in regional anaesthesia and pain management. Drugs. 2010;70:761–91.
    1. Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65:2675–717.
    1. Neal JM, Bernards CM, Butterworth JF, 4th, Di Gregorio G, Drasner K, Hejtmanek MR, Mulroy MF, Rosenquist RW, Weinberg GL. ASRA practice advisory on local anesthetic systemic toxicity. Reg Anesth Pain Med. 2010;35:152–61.
    1. Kopacz DJ, Allen HW. Accidental intravenous levobupivacaine. Anesth Analg. 1999;89:1027–9.
    1. Salomäki TE, Laurila PA, Ville J. Successful resuscitation after cardiovascular collapse following accidental intravenous infusion of levobupivacaine during general anesthesia. Anesthesiology. 2005;103:1095–6.
    1. Plowman AN, Bolsin S, Mather LE. Central system toxicity attributable to epidural ropivacaine hydrochloride. Anesth Intens Care. 1998;26:204–6.
    1. Ruetsch YA, Fattinger KE, Borgeat A. Ropivacaine-induced convulsions and severe cardiac dysrhythmia after sciatic block. Anesthesiology. 1999;90:1784–6.
    1. Ala-Kokko TI, Löppönen A, Alahuhta S. Two instances of central nervous system toxicity in the same patient following repeated ropivacaine-induced brachial plexus block. Acta Anaesthesiol Scand. 2000;44:623–6.
    1. Müller M, Litz RJ, Hüler M, Albrecht DM. Grand mal convulsion and plasma concentrations after intravascular injection of ropivacaine for axillary brachial plexus blockade. Br J Anaesth. 2001;87:784–7.
    1. Petitjeans F, Mion G, Puidupin M, Tourtier JP, Hutson C, Saissy JM. Tachycardia and convulsions induced by accidental intravascular ropivacaine injection during sciatic block. Acta Anaesthesiol Scand. 2002;46:616–7.
    1. Chazalon P, Tourtier JP, Villevielle T, Giraud D, Saïssy JM, Mion G, Benhamou D. Ropivacaine-induced cardiac arrest after peripheral nerve block: successful resuscitation. Anesthesiology. 2003;99:1449–51.
    1. Huet O, Eyrolle LJ, Mazoit JX, Ozier YM. Cardiac arrest after injection of ropivacaine for posterior lumbar plexus blockade. Anesthesiology. 2003;99:1451–3.
    1. Kimura Y, Kamada Y, Kimura A, Orimo K. Ropivacaine-induced toxicity with overdose suspected after axillary brachial plexus block. J Anesth. 2007;21:413–6.
    1. Dhir S, Ganapathy S, Lindsay P, Athwal GS. Case report: ropivacaine neurotoxicity at clinical doses in interscalene brachial plexus block. Can J Anaesth. 2007;54:912–6.
    1. Satsumae T, Tanaka M, Saito S, Inomata S. Convulsions after ropivacaine 300 mg for brachial plexus block. Br J Anaesth. 2008;101:860–2.
    1. Gnaho A, Eyrieux S, Gentili M. Cardiac arrest during an ultrasound-guided sciatic nerve block combined with nerve stimulation. Reg Anesth Pain Med. 2009;34:278.
    1. Hübler M, Gäbler R, Ehm B, Oertel R, Gama de Abreu M, Koch T. Successful resuscitation following ropivacaine-induced systemic toxicity in a neonate. Anaesthesia. 2010;65:1137–40.
    1. Mizutani K, Oda Y, Sato H. Successful treatment of ropivacaine-induced central nervous system toxicity by use of lipid emulsion: effect on total and unbound plasma fractions. J Anesth. 2011;25:442–5.
    1. Chang DH, Ladd LA, Copeland S, Iglesias MA, Plummer JL, Mather LE. Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. Br J Pharmacol. 2001;132:649–58.
    1. Launo C, Gastaldo P, Piccardo F, Palermo S, Demartini A, Grattarola C. Perioperative thoracic epidural analgesia in aortic surgery: role of levobupivacaine. Minerva Anestesiol. 2003;69:751–64.
    1. Casati A, Santorsola R, Aldegheri G, Ravasi F, Fanelli G, Berti M, Fraschini G, Torri G. Intraoperative epidural anesthesia and postoperative analgesia with levobupivacaine for major orthopedic surgery: a double-blind, randomized comparison of racemic bupivacaine and ropivacaine. J Clin Anesth. 2003;15:126–31.
    1. Cusato M, Niebel T, Bettinelli S, Regazzi M. How pharmacokinetic can help to choose the right local anesthetics during epidural infusion. Eur J Pain Suppl. 2011;5:471–5.
    1. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials) CONSORT Group (Consolidated Standards of Reporting Trials) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–91.
    1. Zanen P, Lammers JW. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol. 1995;48:179–84.
    1. Shafer NJ, Sullivan JA. A simulation study of a test for the equality of the coefficients of variation. Commun Stat Simulat. 1986;15:681–95.
    1. Bennett BM. On an approximate test for homogeneity of coefficients of variation. In: Ziegler WJ, editor. In: Contributions to Applied Statistics. Experientia Supplementum. Vol. 22. Basel, Switzerland: Springer; 1976. pp. 169–71.
    1. McKay AT. Distribution of the coefficient of variation and the extended ‘t’ distribution. J R Stat Soc. 1932;95:695–8.
    1. Vangel MG. Confidence intervals for a normal coefficient of variation. Am Stat. 1996;15:21–6.
    1. Cusato M, Allegri M, Niebel T, Ingelmo P, Broglia M, Braschi A, Regazzi M. Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. Eur J Clin Pharmacol. 2011;67:399–406.
    1. Bardsley H, Gristwood R, Baker H, Watson N, Nimmo W. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1998;46:245–9.
    1. Simon MJ, Veering BT, Stienstra R, van Kleef JW, Burm AG. Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. Br J Anaesth. 2004;93:512–20.
    1. Simon MJ, Veering BT, Vletter AA, Stienstra R, van Kleef JW, Burm AG. The effect of age on the systemic absorption and systemic disposition of ropivacaine after epidural administration. Anesth Analg. 2006;102:276–82.
    1. Olofsen E, Burm AG, Simon MJ, Veering BT, van Kleef JW, Dahan A. Population pharmacokinetic-pharmacodynamic modeling of epidural anesthesia. Anesthesiology. 2008;109:664–74.
    1. Di Gregorio G, Neal JM, Rosenquist RW, Weinberg GL. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med. 2010;35:181–7.
    1. Reina MA, Franco CD, López A, Dé Andrés JA, van Zundert A. Clinical implications of epidural fat in the spinal canal. A scanning electron microscopic study. Acta Anaesthesiol Belg. 2009;60:7–17.
    1. Reina MA, Pulido P, Castedo J, Villanueva MC, Lopez A, Sola RG. Characteristics of normal human epidural fat. Rev Esp Anestesiol Reanim. 2006;53:363–72.
    1. De Andres J, Reina MA, Prats A. Epidural space and regional anesthesia. Eur J Pain Suppl. 2009;3:55–63.
    1. Booker PD, Taylor C, Saba G. Perioperative changes in alpha 1-acid glycoprotein concentrations in infants undergoing major surgery. Br J Anaesth. 1996;76:365–8.
    1. Erichsen CJ, Sjövall J, Kehlet H, Hedlund C, Arvidsson T. Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief. Anesthesiology. 1996;84:834–42.
    1. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33:313–27.
    1. Denson D, Coyle D, Thompson G, Myers J. Alpha 1-acid glycoprotein and albumin in human serum bupivacaine binding. Clin Pharmacol Ther. 1984;35:409–15.
    1. Ekatodramis G, Borgeat A, Huledal G, Jeppsson L, Westman L, Sjövall J. Continuous interscalene analgesia with ropivacaine 2 mg/ml after major shoulder surgery. Anesthesiology. 2003;98:143–50.
    1. Burm AG, Stienstra R, Brouwer RP, Emanuelsson BM, van Kleef JW. Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery: pharmacokinetic evaluation. Anesthesiology. 2000;93:395–403.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere